JP2017508741A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508741A5
JP2017508741A5 JP2016554498A JP2016554498A JP2017508741A5 JP 2017508741 A5 JP2017508741 A5 JP 2017508741A5 JP 2016554498 A JP2016554498 A JP 2016554498A JP 2016554498 A JP2016554498 A JP 2016554498A JP 2017508741 A5 JP2017508741 A5 JP 2017508741A5
Authority
JP
Japan
Prior art keywords
gglu
desb27
eps
human insulin
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554498A
Other languages
English (en)
Japanese (ja)
Other versions
JP6580583B2 (ja
JP2017508741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053989 external-priority patent/WO2015128403A2/en
Publication of JP2017508741A publication Critical patent/JP2017508741A/ja
Publication of JP2017508741A5 publication Critical patent/JP2017508741A5/ja
Application granted granted Critical
Publication of JP6580583B2 publication Critical patent/JP6580583B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554498A 2014-02-28 2015-02-26 リシン22のイプシロン位においてアシル化された、A22K、desB27、B29R、desB30ヒトインスリン類似体 Active JP6580583B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157215.6 2014-02-28
EP14157215 2014-02-28
PCT/EP2015/053989 WO2015128403A2 (en) 2014-02-28 2015-02-26 Novel insulin derivatives and the medical uses hereof

Publications (3)

Publication Number Publication Date
JP2017508741A JP2017508741A (ja) 2017-03-30
JP2017508741A5 true JP2017508741A5 (enExample) 2018-04-05
JP6580583B2 JP6580583B2 (ja) 2019-09-25

Family

ID=50184804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554498A Active JP6580583B2 (ja) 2014-02-28 2015-02-26 リシン22のイプシロン位においてアシル化された、A22K、desB27、B29R、desB30ヒトインスリン類似体

Country Status (23)

Country Link
US (1) US10040839B2 (enExample)
EP (1) EP3110840B1 (enExample)
JP (1) JP6580583B2 (enExample)
KR (1) KR20160125988A (enExample)
CN (1) CN106459171B (enExample)
AR (1) AR099569A1 (enExample)
AU (1) AU2015222135B2 (enExample)
BR (1) BR112016017193A2 (enExample)
CA (1) CA2941103A1 (enExample)
DK (1) DK3110840T3 (enExample)
ES (1) ES2831848T3 (enExample)
HR (1) HRP20201732T1 (enExample)
HU (1) HUE051355T2 (enExample)
IL (1) IL246757B (enExample)
MX (1) MX368387B (enExample)
PL (1) PL3110840T3 (enExample)
PT (1) PT3110840T (enExample)
RS (1) RS61137B1 (enExample)
RU (1) RU2684456C2 (enExample)
SA (1) SA516371705B1 (enExample)
SI (1) SI3110840T1 (enExample)
TW (1) TWI686403B (enExample)
WO (1) WO2015128403A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170028031A1 (en) * 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
CA2996455A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CA3294636A1 (en) * 2016-11-21 2026-02-10 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
KR101909052B1 (ko) * 2017-02-09 2018-10-17 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー/エス オリゴマー伸長インスリン−Fcコンジュゲート
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
PE20211264A1 (es) * 2017-08-17 2021-07-15 Novo Nordisk As Analogos de insulina acilados novedosos y usos de estos
MA50414A (fr) 2017-10-19 2020-08-26 Mona E Buice Composition à usage topique pour la cicatrisation améliorée des plaies ouvertes
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
US12178879B2 (en) 2019-02-13 2024-12-31 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative and antibody-drug conjugate thereof
WO2020166600A1 (ja) 2019-02-13 2020-08-20 大日本住友製薬株式会社 システイン残基を有するヘミアスタリン誘導体
ES3049784T3 (en) * 2019-08-27 2025-12-18 Zp Spv 3 K/S Compstatin analogues and their medical uses
FI4073097T3 (fi) 2019-12-11 2024-08-13 Novo Nordisk As Uusia insuliinianalogeja ja niiden käyttötapoja
CN118772259A (zh) * 2019-12-30 2024-10-15 甘李药业股份有限公司 胰岛素衍生物
KR20240013778A (ko) * 2021-05-24 2024-01-30 선샤인 레이크 파르마 컴퍼니 리미티드 신규한 아실화된 인슐린 유사체

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
JP3122128B2 (ja) * 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CA2215694A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
IL131796A0 (en) 1997-03-20 2001-03-19 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
ES2202899T3 (es) 1997-10-24 2004-04-01 Novo Nordisk A/S Agregados de derivados de la insulina humana.
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
SV1998000125A (es) 1997-10-24 1999-05-24 Lilly Co Eli Composiciones de insulina insoluble ref. x-11232
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
EP1086130A1 (en) 1998-06-12 2001-03-28 Kings College London Insulin analogue
AU5454200A (en) 1999-06-29 2001-01-31 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
WO2001093837A2 (en) 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003048195A2 (en) 2001-12-02 2003-06-12 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
KR101159559B1 (ko) 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
CN102552917A (zh) 2003-08-13 2012-07-11 比奥孔有限公司 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー/エス 単鎖インシュリン
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
MX2007000883A (es) 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
JP5410020B2 (ja) 2005-02-02 2014-02-05 ノヴォ ノルディスク アー/エス インスリン誘導体
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
WO2008013938A2 (en) 2006-07-27 2008-01-31 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
EP2404934A1 (en) * 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
WO2009060071A1 (en) 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
ES2612736T3 (es) 2007-11-16 2017-05-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
MX2010009850A (es) * 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
CA2738615A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
PT2459171T (pt) * 2009-07-31 2017-08-16 Sanofi Aventis Deutschland Composição de insulina de atuação longa
EP2569002B1 (en) 2010-05-10 2016-10-26 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011161125A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
CN103415300B (zh) 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
CN103596584B (zh) * 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
AU2012328407A1 (en) 2011-10-27 2014-05-22 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations

Similar Documents

Publication Publication Date Title
JP2017508741A5 (enExample)
RU2016135543A (ru) Новые производные инсулина и их применение в медицине
RU2012128547A (ru) Дважды ацилированные производные glp-1
CY1125006T1 (el) Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2013543853A5 (enExample)
JP2018506507A5 (enExample)
WO2011075393A3 (en) Glucagon/glp-1 receptor co-agonists
JP2014501712A5 (enExample)
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
JP2013533227A5 (enExample)
JP2014529629A5 (enExample)
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
JP2014503526A5 (enExample)
AR082995A1 (es) Profarmacos que comprenden un conjugado de conector de exendina
EA200701746A1 (ru) Фармацевтические композиции для лечения или профилактики заболеваний, в том числе ожирения, диабета, метаболического синдрома, нейродегенеративных заболеваний и заболеваний, связанных с нарушением деятельности митохондрий
JP2019526537A5 (enExample)
MY189770A (en) Biaryl derivative as gpr120 agonists
RU2012150108A (ru) Аналоги глюкагоноподобного пептида-1 и их применение
JP2018505859A5 (enExample)
JP2013530974A5 (enExample)
JP2015513544A5 (enExample)
NZ594244A (en) Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof
JP2015514797A5 (enExample)